<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03141463</url>
  </required_header>
  <id_info>
    <org_study_id>Vvax001-UMCG-01</org_study_id>
    <secondary_id>2015-004979-74</secondary_id>
    <secondary_id>NL56680.000.16</secondary_id>
    <nct_id>NCT03141463</nct_id>
  </id_info>
  <brief_title>Vvax001 Cancer Vaccine in (Pre) Malignant Cervical Lesions</brief_title>
  <official_title>Immune Modulating Effects and Safety of Vvax001, a Therapeutic Semliki Forest Virus Based Cancer Vaccine, in Patients With a History of (Pre) Malignant Cervical Lesions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ViciniVax B.V</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immune modulating effects and safety of Vvax001; different dosages will be tested in patients
      with a history of (pre) malignant cervical lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vvax001 is a therapeutic cancer vaccine consisting of a replication-incompetent Semliki
      Forest Virus (SFV) vector encoding HPV-derived tumor antigens. Patients will receive three
      consecutive doses, with an interval of 3 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 13, 2017</start_date>
  <completion_date type="Actual">November 28, 2017</completion_date>
  <primary_completion_date type="Actual">November 28, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Day 28-31 and day 49-52 after first administration of Vvax001</time_frame>
    <description>To assess the immunological activity of Vvax001 by monitoring HPV-16 E6,7-specific T-cell immune responses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>up to 49-52 days after first administration of Vvax001</time_frame>
    <description>To monitor the side effects/ adverse events related to intramuscular administration of Vvax001. Toxicity will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>CIN 2/3</condition>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Vvax001 therapeutic cancer vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive three consecutive doses of Vvax001, with an interval of 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vvax001 therapeutic cancer vaccine</intervention_name>
    <description>Vvax001 is a vaccine consisting of a replication-incompetent Semliki Forest Virus (SFV) vector encoding HPV-derived tumor antigens. Patients will receive three consecutive doses, with an interval of 3 weeks.</description>
    <arm_group_label>Vvax001 therapeutic cancer vaccine</arm_group_label>
    <other_name>rSFVeE6,7</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A history of CIN II and III OR cervical cancer

          -  Minimally 12 weeks after completion of treatment

          -  Age of 18 years and older

          -  Baseline laboratory findings; adequate hepatic, renal ,and bone marrow function, HIV-
             and HBV-negative

          -  Patients of child-bearing potential should test negative using a serum pregnancy test
             and agree to utilize effective contraception during the entire treatment and follow-up
             period of the study

          -  Written informed consent according to local guidelines

        Exclusion Criteria:

          -  Prior treatment with immunotherapeutic agents against HPV

          -  History of an autoimmune disease or other systemic intercurrent disease that might
             affect the immunocompetence of the patient, or current or prior use (4 weeks before
             start of the study) of high dose immunosuppressive therapy.

          -  History of a second malignancy except curatively treated low-stage tumors with a
             histology that can be differentiated from the cervical cancer type

          -  Participation in a study with another investigational drug within 30 days prior to the
             enrolment in this study

          -  Any condition that in the opinion of the investigator could interfere with the conduct
             of the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R Yigit, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Daemen T, Riezebos-Brilman A, Regts J, Dontje B, van der Zee A, Wilschut J. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization. Antivir Ther. 2004 Oct;9(5):733-42.</citation>
    <PMID>15535411</PMID>
  </reference>
  <reference>
    <citation>Riezebos-Brilman A, Walczak M, Regts J, Rots MG, Kamps G, Dontje B, Haisma HY, Wilschut J, Daemen T. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer. Gene Ther. 2007 Dec;14(24):1695-704. Epub 2007 Oct 11.</citation>
    <PMID>17928874</PMID>
  </reference>
  <reference>
    <citation>Draghiciu O, Boerma A, Hoogeboom BN, Nijman HW, Daemen T. A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development. Oncoimmunology. 2015 May 27;4(10):e1029699. eCollection 2015 Oct.</citation>
    <PMID>26451295</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2017</study_first_submitted>
  <study_first_submitted_qc>May 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2017</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Refika Yigit</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>Therapeutic vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

